Physician profile
Amanda Vansant
NPI 1295071496
$11,777.79
in general payments reported to CMS, 2019-2025
23 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,912 · 2022: $3,188 · 2023: $1,283 · 2024: $1,829 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,678.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,191.46 | 2021-2025 | |
| Alkermes, INC. | $1,210.37 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $418.99 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $405.20 | 2022-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $394.79 | 2021-2024 | Jornay Pm |
| Corium, LLC | $343.05 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $300.29 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $206.80 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $181.48 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $180.28 | 2023-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $140.35 | 2022-2025 | Uzedy |
| Biogen, INC. | $139.97 | 2024-2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $123.81 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $122.70 | 2021-2023 | Trintellix |
| Neuronetics, INC. | $99.72 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.75 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $62.22 | 2021-2025 | Invega Sustenna, Spravato |
| Lundbeck LLC | $39.74 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $37.06 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $35.23 | 2023-2024 | Quviviq |
| Eisai INC. | $21.36 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.72 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.45 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Vansant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.